Is Eli Lilly & Co. (LLY-N) Buy or Sell — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Eli Lilly & Co. (LLY-N)

NYSE:LLY

330.97

0.11 (0.03%) 1d

DON'T BUY

Has done well. Their diabetes drug is effective for weight loss, which is pending approval, but would open a new market. She expects approval. Stock price reflects this approval though. Weight loss is a lucrative market given obesity levels around the world. The PE is too high for her, but may buy on a pullback.

biotechnology / pharmaceutical

Unspecified

The whole drug industry has been under pressure for the past 30 years and is having more and more trouble coming up with new drugs. R&D costs are increasing so he doesn't like the pharmaceutical industry in general. In response to a question regarding the currency component he doesn't feel it is an issue.

biotechnology / pharmaceutical

Unspecified

It has outperformed the sector. The technicals are OK but but it is not in a great space. He owns some but would not buy more at this time.

biotechnology / pharmaceutical

BUY

It reports Thursday. He thinks their new drug will be the biggest seller of all time. He owns a lot of shares.

biotechnology / pharmaceutical

BUY

Just announced a $450 million commitment to develop a promising diabetes drug that helps weight loss. The stock still has legs.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Mar 14/22, Up 34%) Great company with high demand product (insulin). Building R&D portfolio that is on cutting edge. New drugs in the pipeline that will be approved. Weight loss products look promising.

biotechnology / pharmaceutical

PARTIAL BUY

Owns a big positions. Is a conservative company that doesn't hype itself or drugs which turns off some investors. Amazing diabetes, obesity and potentially Alzheimer drugs. Are having an analyst meeting on Tuesday, so wait after that to buy.

biotechnology / pharmaceutical

TOP PICK

Super-excited about long-term prospects from new products, which could lead to 40% sales growth by 2025-26. These products will also increase margins. Biggest opportunity is within weight loss, initial results of a 3-year study are looking good, targeting obesity as well as its complications. Not cheap, but will continue to outperform. Yield is 1.05%. (Analysts’ price target is $381.39)

biotechnology / pharmaceutical

BUY on WEAKNESS

Allan Tong’s Discover Picks You could then take that money and put it in Eli Lilly. There’s potential in LLY stock’s own Alzheimer’s drug. Also, the street is putting its hopes into LLY’s weight-loss drug, Mounjaro, when it starts selling in two or three years. After all, diabetes as at an all-time high in America. One analyst envisioned $25 billion in peak sales, outstripping AbbVie‘s Humira which has topped $20.7 billion. However, the street is getting a little ahead of itself, since the FDA has approved Mounjaro for glycemic control in T2D patients, and LLY still needs to submit the drug as a treatment for weight-loss. Read Mixed bag of 3 Defensive Stocks for our full analysis.

biotechnology / pharmaceutical

BUY on WEAKNESS

A big holding. He almost bought more now. The drug stocks can go lower, but the future for Eli's weight-loss drug is huge and could be good for their Alzheimer's drug. Buy more when it breaks $280s.

biotechnology / pharmaceutical

BUY

Plenty of upside from its improved diabetes and obesity drug. Their Alzheimer's drug has potential As a drugmaker, it won't be hostage to a recession. Drugs will keep selling.

biotechnology / pharmaceutical

BUY

Around 15% topline growth. Likes healthcare, great fundamentals and 23% expected EPS growth.

biotechnology / pharmaceutical

BUY

Focusing on its diabetes and weight loss drug. The weight loss drug could be one of the biggest drugs of all time, when it starts selling in the next 2-3 years.

biotechnology / pharmaceutical

BUY

It seems cheap, because they have 4-7 billion-dollar drugs in their pipeline. So, estimates will have to move up dramatically and the PE will be lower. Therefore, the stock doesn't look as expensive as it seems.

biotechnology / pharmaceutical

BUY

LLY vs. NVO NVO is focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.

biotechnology / pharmaceutical

Showing 1 to 15 of 72 entries

«
‹
1
2
3
4
5
›
»

Next Page

Eli Lilly & Co.(LLY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 12

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 13

Stockchase rating for Eli Lilly & Co. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Eli Lilly & Co.(LLY-N) Frequently Asked Questions

What is Eli Lilly & Co. stock symbol?

Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N

Is Eli Lilly & Co. a buy or a sell?

In the last year, 13 stock analysts published opinions about LLY-N. 12 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..

Is Eli Lilly & Co. a good investment or a top pick?

Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..

Why is Eli Lilly & Co. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Eli Lilly & Co. worth watching?

13 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.

What is Eli Lilly & Co. stock price?

On 2023-03-22, Eli Lilly & Co. (LLY-N) stock closed at a price of $330.97.

You may also like:

PWC-T KRN-T MEL-N MSTR-Q ENVX-Q SLY-T CA-N FHN-N NAU-T VOLAF-OTC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.